M
Magdalena Winiarska
Researcher at Medical University of Warsaw
Publications - 69
Citations - 1562
Magdalena Winiarska is an academic researcher from Medical University of Warsaw. The author has contributed to research in topics: Immunotherapy & CD20. The author has an hindex of 20, co-authored 60 publications receiving 1267 citations.
Papers
More filters
Journal ArticleDOI
Aminolevulinic Acid (ALA) as a Prodrug in Photodynamic Therapy of Cancer
Malgorzata Wachowska,Angelika Muchowicz,Malgorzata Firczuk,Magdalena Gabrysiak,Magdalena Winiarska,Malgorzata Wanczyk,Kamil Bojarczuk,Jakub Golab +7 more
TL;DR: Since PpIX is a potent photosensitizer this metabolic pathway can be exploited in photodynamic therapy (PDT), this is an already approved therapeutic strategy making ALA one of the most successful prodrugs used in cancer treatment.
Journal ArticleDOI
Cardiotoxicity of the Anticancer Therapeutic Agent Bortezomib
Dominika Nowis,Michal Maczewski,Urszula Mackiewicz,Marek Kujawa,Anna Ratajska,Mariusz R. Wieckowski,Grzegorz M. Wilczynski,Monika Malinowska,Jacek Bil,Pawel Salwa,Marek Bugajski,Cezary Wojcik,Maciej Siński,Piotr Abramczyk,Magdalena Winiarska,Anna Dabrowska-Iwanicka,Jerzy Duszyński,Marek Jakóbisiak,Jakub Golab,Jakub Golab +19 more
TL;DR: It is indicated that bortezomib treatment leads to left ventricular contractile dysfunction manifested by a significant drop in left ventricle ejection fraction.
Journal ArticleDOI
Statins impair antitumor effects of rituximab by inducing conformational changes of CD20.
Magdalena Winiarska,Jacek Bil,Ewa Wilczek,Grzegorz M. Wilczynski,Małgorzata Lekka,Patrick J. Engelberts,Wendy J.M. Mackus,Elżbieta Górska,Lukasz Bojarski,Tomasz Stoklosa,Dominika Nowis,Zuzanna Kurzaj,Marcin Makowski,Eliza Glodkowska,Tadeusz Issat,Piotr Mrowka,Witold Lasek,Anna Dabrowska-Iwanicka,Grzegorz W. Basak,M Wasik,Krzysztof Warzocha,Maciej Siński,Zbigniew Gaciong,Marek Jakóbisiak,Paul W. H. I. Parren,Jakub Golab +25 more
TL;DR: Statins were shown to interfere with both detection of CD20 and antilymphoma activity of rituximab, which has significant clinical implications, as impaired binding of mAbs to conformational epitopes ofCD20 elicited by statins could delay diagnosis, postpone effective treatment, or impair anti-lymphomaactivity of r ituximabs.
Journal ArticleDOI
Antitumor Immunity Triggered by Melphalan Is Potentiated by Melanoma Cell Surface-Associated Calreticulin
Aleksandra M. Dudek-Peric,Gabriela B Ferreira,Angelika Muchowicz,Jasper Wouters,Nicole Prada,Shaun Martin,Santeri Kiviluoto,Magdalena Winiarska,Louis Boon,Chantal Mathieu,Joost van den Oord,Marguerite Stas,Marie-Lise Gougeon,Jakub Golab,Jakub Golab,Abhishek D. Garg,Patrizia Agostinis +16 more
TL;DR: Melphalan administration in vivo could stimulate a CD8(+) T cell-dependent protective antitumor response and was potentiated in combination with exogenous calreticulin, but not tumor necrosis factor, a cytokine often combined with Mel-ILP.
Journal ArticleDOI
Zinc protoporphyrin IX, a heme oxygenase-1 inhibitor, demonstrates potent antitumor effects but is unable to potentiate antitumor effects of chemotherapeutics in mice.
Dominika Nowis,Marek Bugajski,Magdalena Winiarska,Jacek Bil,Angelika Szokalska,Pawel Salwa,Tadeusz Issat,Halina Was,Alicja Jozkowicz,Jozef Dulak,Tomasz Stoklosa,Jakub Golab +11 more
TL;DR: Inhibition of HO-1 exerts antitumor effects but should not be used to potentiate antitumors effects of cancer chemotherapeutics unless procedures of selective tumor targeting of HO -1 inhibitors are developed.